###begin article-title 0
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 81 86 <span type="species:ncbi:9606">human</span>
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components
###end article-title 0
###begin p 1
T. Strowig and C. Gurer contributed equally to this paper.
###end p 1
###begin p 2
###xml 840 841 836 837 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 849 850 845 846 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 26 31 <span type="species:ncbi:9606">human</span>
###xml 52 58 <span type="species:ncbi:9606">humans</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 296 301 <span type="species:ncbi:9606">human</span>
###xml 379 397 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 399 402 <span type="species:ncbi:10376">EBV</span>
###xml 474 479 <span type="species:ncbi:9606">human</span>
###xml 532 535 <span type="species:ncbi:10376">EBV</span>
###xml 598 603 <span type="species:ncbi:9606">human</span>
###xml 604 607 <span type="species:ncbi:10376">EBV</span>
###xml 649 652 <span type="species:ncbi:10376">EBV</span>
###xml 699 702 <span type="species:ncbi:10376">EBV</span>
###xml 780 783 <span type="species:ncbi:10376">EBV</span>
###xml 901 906 <span type="species:ncbi:10090">mouse</span>
###xml 959 962 <span type="species:ncbi:10376">EBV</span>
Many pathogens that cause human disease infect only humans. To identify the mechanisms of immune protection against these pathogens and also to evaluate promising vaccine candidates, a small animal model would be desirable. We demonstrate that primary T cell responses in mice with reconstituted human immune system components control infection with the oncogenic and persistent Epstein-Barr virus (EBV). These cytotoxic and interferon-gamma-producing T cell responses were human leukocyte antigen (HLA) restricted and specific for EBV-derived peptides. In HLA-A2 transgenic animals and similar to human EBV carriers, T cell responses against lytic EBV antigens dominated over recognition of latent EBV antigens. T cell depletion resulted in elevated viral loads and emergence of EBV-associated lymphoproliferative disease. Both loss of CD4+ and CD8+ T cells abolished immune control. Therefore, this mouse model recapitulates features of symptomatic primary EBV infection and generates T cell-mediated immune control that resists oncogenic transformation.
###end p 2
###begin p 3
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 123 128 <span type="species:ncbi:10090">mouse</span>
###xml 133 136 <span type="species:ncbi:9606">man</span>
###xml 306 311 <span type="species:ncbi:9606">human</span>
###xml 316 321 <span type="species:ncbi:10090">mouse</span>
Mice are a preferred species for many avenues of immunological research in vivo. Because of the evolutionary divergence of mouse and man 65 million years ago, however, these two species have inhabited different ecological niches and have been challenged with minimally overlapping groups of pathogens. The human and mouse immune systems, evolving to meet these challenges, have therefore accumulated many differences (1), making genes related to immunity, together with genes involved in reproduction and olfaction, the most divergent between the two species (2).
###end p 3
###begin p 4
###xml 415 416 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">3</xref>
###xml 418 419 414 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 578 579 574 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 1593 1594 1589 1590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 1596 1597 1592 1593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 78 84 <span type="species:ncbi:9606">humans</span>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
###xml 193 196 <span type="species:ncbi:10376">EBV</span>
###xml 200 205 <span type="species:ncbi:9606">human</span>
###xml 249 254 <span type="species:ncbi:9606">human</span>
###xml 273 279 <span type="species:ncbi:9606">Humans</span>
###xml 321 324 <span type="species:ncbi:10376">EBV</span>
###xml 422 425 <span type="species:ncbi:10376">EBV</span>
###xml 586 589 <span type="species:ncbi:10376">EBV</span>
###xml 641 644 <span type="species:ncbi:10376">EBV</span>
###xml 669 672 <span type="species:ncbi:10376">EBV</span>
###xml 738 741 <span type="species:ncbi:10376">EBV</span>
###xml 789 792 <span type="species:ncbi:10376">EBV</span>
###xml 875 878 <span type="species:ncbi:10376">EBV</span>
###xml 1110 1118 <span type="species:ncbi:9606">patients</span>
###xml 1125 1128 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1301 1304 <span type="species:ncbi:10376">EBV</span>
###xml 1386 1389 <span type="species:ncbi:10376">EBV</span>
###xml 1431 1434 <span type="species:ncbi:10376">EBV</span>
###xml 1474 1477 <span type="species:ncbi:10376">EBV</span>
###xml 1504 1507 <span type="species:ncbi:10376">EBV</span>
###xml 1682 1685 <span type="species:ncbi:10376">EBV</span>
###xml 1777 1780 <span type="species:ncbi:10376">EBV</span>
###xml 1817 1820 <span type="species:ncbi:10376">EBV</span>
Pathogens that drive this divergence are those that exclusively infect either humans or mice with a high frequency of population penetration and life-threatening pathology. One such example is EBV, a human gamma-herpesvirus that infects >90% of the human adult population. Humans are the only known natural reservoir for EBV, and this virus is associated with malignancies of lymphocyte and epithelial cell origin (3, 4). EBV is thought to cause or contribute to these life-threatening tumors by its ability to induce proliferation and to protect infected cells from apoptosis (5). All EBV-associated lymphomas and carcinomas express latent EBV antigens, whereas lytic EBV particle production does not cause significant pathology. Latent EBV antigen expression differs between the various EBV-associated malignancies. Burkitt lymphoma expresses only the nuclear antigen 1 of EBV (EBNA1) as the sole latent gene product (latency I). In contrast, Hodgkin lymphoma and nasopharyngeal carcinoma express, in addition, one or both latent membrane proteins (LMPs), LMP1 and 2 (latency II). Only in immune-compromised patients, like HIV-infected individuals or transplant recipients, do B cell lymphomas occur that express the five additional EBNA proteins 2, 3A, B, C, and LP (latency III). In addition, all EBV-infected B cells express small nontranslated virally encoded RNAs, including the EBV-encoded RNAs (EBERs). All three types of EBV latencies can also be found in healthy EBV carriers, and this graded EBV protein expression depends on the B cell differentiation stage of the infected cell (6, 7). Healthy virus carriers therefore have already established tumor-associated latent EBV protein expression. Hence, the increased risk of immune-compromised individuals to develop EBV-associated tumors indicates loss of EBV-specific immune control that normally prevents viral tumorigenesis.
###end p 4
###begin p 5
###xml 221 222 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 254 255 254 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 513 514 513 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 529 530 529 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 623 624 623 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 708 709 708 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 819 820 819 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 828 829 828 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 943 944 943 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 952 953 952 953 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1031 1033 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 1080 1081 1080 1081 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1102 1103 1102 1103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1113 1115 1113 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 45 48 <span type="species:ncbi:10376">EBV</span>
###xml 140 143 <span type="species:ncbi:10376">EBV</span>
###xml 180 183 <span type="species:ncbi:10376">EBV</span>
###xml 286 289 <span type="species:ncbi:10376">EBV</span>
###xml 329 332 <span type="species:ncbi:10376">EBV</span>
###xml 559 562 <span type="species:ncbi:10376">EBV</span>
###xml 915 918 <span type="species:ncbi:10376">EBV</span>
T cells constitute the decisive component of EBV-specific immune control against virus-associated malignancies because adoptive transfer of EBV-specific T cell lines can eradicate EBV-associated posttransplant lymphomas (8). During primary infection, CD8+ T cells targeting epitopes of EBV lytic antigens make up the majority of EBV-specific T cells, but T cells targeting latent epitopes can also be detected. Different latency patterns confer different degrees of immunogenicity for recognition by cytotoxic CD8+ and helper CD4+ T cells (9, 10). In healthy EBV carriers, the EBNA3 proteins are the dominant targets of CD8+ T cell responses, whereas EBNA1, 2, and 3C are the most consistently recognized CD4+ T cell antigens. In contrast, the LMPs are subdominant T cell antigens. At least a subset of investigated CD4+ and CD8+ T clones, however, recognize both dominant and subdominant specificities directly on EBV-infected cells. Both CD4+ and CD8+ T cells therefore contribute to immune control against virus-infected cells (11), in addition to maintenance of functional CD8+ T cell memory by CD4+ T cells (12).
###end p 5
###begin p 6
###xml 687 690 687 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 696 697 692 693 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 697 700 693 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 841 843 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 845 847 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 885 889 881 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 895 896 887 888 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 896 899 888 891 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 945 947 937 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">15</xref>
###xml 949 951 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 1192 1196 1184 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 1244 1246 1236 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 31 34 <span type="species:ncbi:10376">EBV</span>
###xml 163 166 <span type="species:ncbi:10376">EBV</span>
###xml 301 304 <span type="species:ncbi:10376">EBV</span>
###xml 332 337 <span type="species:ncbi:10090">Mouse</span>
###xml 373 378 <span type="species:ncbi:9606">human</span>
###xml 522 525 <span type="species:ncbi:10376">EBV</span>
###xml 600 605 <span type="species:ncbi:9606">human</span>
###xml 701 705 <span type="species:ncbi:10090">mice</span>
###xml 900 904 <span type="species:ncbi:10090">mice</span>
###xml 933 938 <span type="species:ncbi:9606">human</span>
###xml 1001 1006 <span type="species:ncbi:9606">human</span>
###xml 1086 1091 <span type="species:ncbi:10090">mouse</span>
###xml 1124 1129 <span type="species:ncbi:9606">human</span>
###xml 1197 1201 <span type="species:ncbi:10090">mice</span>
###xml 1310 1314 <span type="species:ncbi:10090">mice</span>
###xml 1334 1339 <span type="species:ncbi:9606">human</span>
###xml 1437 1442 <span type="species:ncbi:10090">mouse</span>
###xml 1453 1458 <span type="species:ncbi:9606">human</span>
###xml 1674 1680 <span type="species:ncbi:9606">humans</span>
###xml 1743 1747 <span type="species:ncbi:10090">mice</span>
###xml 1845 1848 <span type="species:ncbi:10376">EBV</span>
###xml 1863 1866 <span type="species:ncbi:10376">EBV</span>
The lack of an animal model of EBV infection prevents assignment of a protective value to the known T cell reactivities. Design and evaluation of vaccines against EBV-associated tumors and symptomatic primary infection, however, require knowledge about the degree of protection conferred by different EBV-specific immune responses. Mouse models that partially reconstitute human immune system components after engraftment of hematopoietic progenitor cells (HPCs) are of particular interest to study vaccine candidates and EBV-specific immune responses in vivo. In this respect, three novel models of human immune system reconstitution are being considered. The first one uses BALB/c Rag2-/- gammac-/- mice, which reconstitute macrophages, T cells, B cells, natural killer cells, and dendritic cells after neonatal intrahepatic HPC transfer (13, 14). The second model reconstitutes NOD-scid gammac-/- mice by intravenous injection of human HPCs (15, 16), which also leads to significant development of human myeloid and lymphoid cells. Finally, the most labor-intensive model is the BLT mouse, which requires implantation of human fetal liver and thymus pieces under the kidney capsule of NOD-scid mice in addition to intravenous HPC injection (17). Immune compartment reconstitution in peripheral blood of BLT mice is very similar to human. However, although signs of primary immune responses were reported in all three of these current mouse models of human immune system reconstitution, the protective value of this immunocompetence and, thus, the potential of these in vivo systems as challenge models for vaccine development against pathogens with exclusive tropism for humans has not been evaluated. Therefore, we analyzed the ability of mice with reconstituted immune system components to exert antigen-specific T cell-mediated control of EBV infection and EBV-associated lymphomas.
###end p 6
###begin title 7
RESULTS
###end title 7
###begin title 8
###xml 39 40 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 40 43 36 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 73 74 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
###xml 63 68 <span type="species:ncbi:9606">human</span>
Immune reconstitution of NOD-scid gammac-/- mice injected with human CD34+ HPCs
###end title 8
###begin p 9
###xml 227 231 227 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 237 238 233 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 238 241 234 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 250 253 246 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 259 260 251 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 260 263 252 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 271 273 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 274 276 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 332 335 324 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 341 342 329 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 342 345 330 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 354 358 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 364 365 348 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 365 368 349 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 409 410 393 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 531 535 515 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 541 542 521 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 542 545 522 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 12 16 <span type="species:ncbi:10090">mice</span>
###xml 32 35 <span type="species:ncbi:10376">EBV</span>
###xml 92 95 <span type="species:ncbi:10376">EBV</span>
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 170 175 <span type="species:ncbi:10090">mouse</span>
###xml 187 192 <span type="species:ncbi:9606">human</span>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 379 384 <span type="species:ncbi:9606">human</span>
###xml 489 494 <span type="species:ncbi:9606">human</span>
###xml 546 550 <span type="species:ncbi:10090">mice</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
To generate mice susceptible to EBV infection and, hence, potentially capable of generating EBV-specific human immune responses in vivo, we compared previously described mouse models for human immune system reconstitution (NOD-scid gammac-/- and Rag2-/- gammac-/- mice) (13-16). For this purpose we engrafted irradiated newborn Rag2-/- gammac-/- and NOD-scid gammac-/- mice with human fetal liver-derived CD34+ HPCs. We observed higher levels of overall reconstitution and, in particular, human T and NK cell reconstitution in NOD-scid gammac-/- mice (unpublished data), and therefore pursued this model, which we will refer to as hu-NSG mice in the remainder of the text.
###end p 9
###begin p 10
###xml 176 177 176 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 365 366 365 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 373 374 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 404 405 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 441 442 441 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 586 587 586 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1081 1085 1081 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 1091 1092 1087 1088 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 1092 1095 1088 1091 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 166 171 <span type="species:ncbi:9606">human</span>
###xml 576 581 <span type="species:ncbi:9606">human</span>
###xml 619 624 <span type="species:ncbi:9606">human</span>
###xml 729 733 <span type="species:ncbi:10090">mice</span>
###xml 799 804 <span type="species:ncbi:9606">human</span>
###xml 899 903 <span type="species:ncbi:10090">mice</span>
###xml 1040 1045 <span type="species:ncbi:9606">human</span>
###xml 1096 1100 <span type="species:ncbi:10090">mice</span>
###xml 1198 1203 <span type="species:ncbi:9606">human</span>
We consistently achieved reconstitution of 20-50 hu-NSG mice from the same graft with similar B and T cell frequencies in peripheral blood by 3 mo (). Frequencies of human CD45+ cells routinely exceeded 60% of total splenocytes after 4 mo of reconstitution (Fig. S1 B), with the majority (80-90%) being B and T cells (ratios of 2:1 for B to T cells, and 3:2 for CD4+ to CD8+ T cells). Additionally, CD123+ plasmacytoid cells (1-2%) and CD11c+ conventional dendritic cells (1-2%), monocytes (3-5%), and NK cells (2-5%) also engrafted (Fig. S1 B and not depicted). Furthermore, human CD45+ cells and all major subsets of human immune cells were detected in the thymus, mesenteric lymph node, bone marrow, liver, and lung of hu-NSG mice (unpublished data). Compared with the structured architecture in human secondary lymphoid organs like lymph nodes and tonsils, immune cells in the spleens of hu-NSG mice showed a primitive organization into white and red pulp (Fig. S1 C). In line with previous findings, we therefore successfully achieved human multilineage reconstitution in NOD-scid gammac-/- mice after neonatal HPC transfer, thus generating a small animal model with the potential to generate human immune responses in vivo.
###end p 10
###begin title 11
###xml 0 3 <span type="species:ncbi:10376">EBV</span>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
EBV infection of humanized mice
###end title 11
###begin p 12
###xml 384 386 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 427 428 423 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 621 622 617 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 673 681 669 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 727 728 723 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 791 799 787 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 842 843 838 839 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 885 886 881 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 896 904 892 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 929 930 925 926 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1056 1057 1052 1053 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1166 1174 1162 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 1400 1401 1396 1397 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1420 1421 1416 1417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1507 1515 1503 1511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
###xml 26 31 <span type="species:ncbi:9606">human</span>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 131 134 <span type="species:ncbi:10376">EBV</span>
###xml 149 154 <span type="species:ncbi:9606">human</span>
###xml 369 372 <span type="species:ncbi:10376">EBV</span>
###xml 415 419 <span type="species:ncbi:10090">mice</span>
###xml 503 506 <span type="species:ncbi:10376">EBV</span>
###xml 1131 1134 <span type="species:ncbi:10376">EBV</span>
###xml 1160 1164 <span type="species:ncbi:10090">mice</span>
###xml 1213 1216 <span type="species:ncbi:10376">EBV</span>
###xml 1272 1275 <span type="species:ncbi:10376">EBV</span>
###xml 1492 1495 <span type="species:ncbi:10376">EBV</span>
###xml 1553 1557 <span type="species:ncbi:10090">mice</span>
###xml 1575 1578 <span type="species:ncbi:10376">EBV</span>
###xml 1646 1649 <span type="species:ncbi:10376">EBV</span>
To test the reconstituted human immune system's ability to generate pathogen-specific immune control, we infected hu-NSG mice with EBV, an oncogenic human virus that is efficiently controlled by infected individuals with normal immune function. We chose an infectious dose that would approximate the number of virus particles in 100 microl of saliva from a symptomatic EBV converter (18). After injection of hu-NSG mice with 105 Raji-infecting units (RIU) of purified viral particles intraperitoneally, EBV-infected cells were readily detectable in the spleen 4 wk after infection by in situ hybridization for EBERs. EBER+ cells were not detected in mock-infected animals (Fig. 1 A). At later time points, we also detected EBER+ cells in the lymph nodes and livers of most infected animals (Fig. 1 A). In the spleens of infected animals, EBER+ cells were consistently surrounded by CD3+ T cells (Fig. 1 B). Furthermore, when EBER+ cells were detected in nonlymphoid organs such as liver and kidney, these infected cells were again in close proximity to CD3+ T cells, suggesting that T cells can home to similar peripheral sites as EBV-infected cells in hu-NSG mice (Fig. 1 B). To characterize the latency type of EBV-infected cells, we stained spleen sections for the two EBV-encoded proteins EBNA2 and LMP1. We did not detect any LMP1 single-positive cells, but we found similar frequencies of EBNA2+ compared with EBER+ cells, some of which also expressed LMP1, indicating latency III-type EBV infection (Fig. 1 C). These results indicate that hu-NSG mice establish latent EBV infection, which constitutes the basis of B cell transformation by EBV.
###end p 12
###begin p 13
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EBV-infected cells are detected in hu-NSG mice in multiple organs and express EBNA2 and LMP1.</bold>
###xml 190 191 190 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 229 230 229 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 295 296 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 3 <span type="species:ncbi:10376">EBV</span>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 98 101 <span type="species:ncbi:10376">EBV</span>
###xml 433 436 <span type="species:ncbi:10376">EBV</span>
EBV-infected cells are detected in hu-NSG mice in multiple organs and express EBNA2 and LMP1. (A) EBV-infected cells could be detected in the indicated organs by EBER hybridization. (B) EBER+ cells were surrounded by T cells (CD3+) both in the spleen and after migration to the kidney. (C) EBNA2+ cells coexpressed LMP1 in the spleen (the right panel is a magnification of the left panel). These analyses were performed 4-6 wk after EBV infection. Data are representative of three independent experiments. Bars, 100 microm.
###end p 13
###begin title 14
###xml 30 33 <span type="species:ncbi:10376">EBV</span>
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
Development of HLA-restricted EBV-specific human T cell responses in infected hu-NSG mice
###end title 14
###begin p 15
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 385 386 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 415 416 415 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 507 508 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 540 548 540 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 633 634 633 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 638 639 638 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 703 711 703 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 B</xref>
###xml 742 743 742 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 755 756 755 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 991 992 991 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 113 116 <span type="species:ncbi:10376">EBV</span>
###xml 179 184 <span type="species:ncbi:9606">human</span>
###xml 199 202 <span type="species:ncbi:10376">EBV</span>
###xml 405 410 <span type="species:ncbi:9606">human</span>
###xml 434 437 <span type="species:ncbi:10376">EBV</span>
###xml 525 530 <span type="species:ncbi:9606">human</span>
###xml 697 701 <span type="species:ncbi:10090">mice</span>
###xml 942 948 <span type="species:ncbi:9606">humans</span>
###xml 976 979 <span type="species:ncbi:10376">EBV</span>
Because we rarely observed tumors after 6 wk of infection in hu-NSG mice, we investigated whether they developed EBV-specific T cell responses, such as those that protect healthy human carriers from EBV-associated malignancies (9, 10). For this purpose, we first analyzed the splenic lymphocyte composition of the infected animals by flow cytometry. We found dramatic expansions of CD3+ T cells among the human CD45+ leukocytes after EBV infection, which correlated with an increase in the percentage of CD8+ cells among the human T cells (Fig. 2 A). On average, there was a statistically significant twofold expansion of splenic CD3+ CD8+ T cells in 10 independent experiments with a total of 40 mice (Fig. 2 B). In addition, in both the CD8+ and the CD4+ T cell compartments, there was a marked-up regulation of HLA-DR and CD45RO surface expression, indicating an activated memory phenotype of the expanded T cells, similar to that seen in humans during symptomatic primary EBV infection (9, 10).
###end p 15
###begin p 16
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 52 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Expansion of human CD3<sup>+</sup> T cells after EBV infection.</bold>
###xml 260 261 260 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 269 270 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 450 451 450 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 454 455 454 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 38 41 <span type="species:ncbi:10376">EBV</span>
###xml 85 88 <span type="species:ncbi:10376">EBV</span>
###xml 480 484 <span type="species:ncbi:10090">mice</span>
Expansion of human CD3+ T cells after EBV infection. (A) Splenocytes from control or EBV-infected animals were harvested 6 wk after infection. Frequencies of lymphocyte subsets were determined by flow cytometry. Activation and memory phenotypes of both the CD4+ and CD8+ T cells were monitored by measuring the up-regulation of the HLA-DR and CD45RO surface markers, respectively. Representative data from 10 experiments are shown. (B) Summary of CD3+CD8+ T cell expansion for 40 mice in 10 different experiments. Horizontal bars represent means.
###end p 16
###begin p 17
###xml 728 743 716 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, A and B</xref>
###xml 848 856 836 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 1045 1053 1033 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 1141 1142 1129 1130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1150 1151 1138 1139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 83 86 <span type="species:ncbi:10376">EBV</span>
###xml 136 141 <span type="species:ncbi:9606">human</span>
###xml 288 293 <span type="species:ncbi:10090">mouse</span>
###xml 374 377 <span type="species:ncbi:10376">EBV</span>
###xml 784 787 <span type="species:ncbi:10376">EBV</span>
###xml 817 820 <span type="species:ncbi:10376">EBV</span>
###xml 934 938 <span type="species:ncbi:10090">mice</span>
###xml 1125 1128 <span type="species:ncbi:10376">EBV</span>
###xml 1152 1157 <span type="species:ncbi:9606">human</span>
###xml 1188 1192 <span type="species:ncbi:10090">mice</span>
###xml 1213 1216 <span type="species:ncbi:10376">EBV</span>
We next examined whether T cells from infected animals would respond to autologous EBV-transformed B cells presenting viral antigens by human MHC molecules. For this purpose, we first established lymphoblastoid cell lines (LCLs) by in vitro infection of B cells derived from a littermate mouse reconstituted with cells from the same HPC donor used for reconstitution of the EBV-infected animals. B cell-depleted splenocytes isolated from control and infected animals were incubated with these autologous LCLs, and IFN-gamma secretion was monitored by ELISPOT assays. Autologous LCLs stimulated significant amounts of IFN-gamma production, whereas responses to allogeneic LCLs were comparable to background IFN-gamma production (Fig. 3, A and B). Animals infected with higher doses of EBV also developed more vigorous EBV-specific T cell responses (Fig. 3 A), indicating that T cells can be primed in a dose-dependent manner in hu-NSG mice. Pretreatment of LCLs with antibodies against HLA-A/B/C, HLA-DR/DP/DQ, or both blocked their recognition (Fig. 3 B and not depicted). These data clearly demonstrate that HLA-restricted, EBV-specific CD8+ and CD4+ human T cells were primed in hu-NSG mice upon infection with EBV.
###end p 17
###begin p 18
###xml 0 127 0 127 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dose-dependent induction of HLA-restricted T cell responses against autologous EBV-transformed B cells in infected hu-NSG mice.</bold>
###xml 176 177 176 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 183 184 183 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 409 410 401 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 586 587 578 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 79 82 <span type="species:ncbi:10376">EBV</span>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
###xml 189 192 <span type="species:ncbi:10376">EBV</span>
###xml 216 221 <span type="species:ncbi:9606">human</span>
###xml 281 284 <span type="species:ncbi:10376">EBV</span>
###xml 323 326 <span type="species:ncbi:10376">EBV</span>
###xml 470 474 <span type="species:ncbi:10090">mice</span>
###xml 560 564 <span type="species:ncbi:10090">mice</span>
###xml 592 595 <span type="species:ncbi:10376">EBV</span>
###xml 915 920 <span type="species:ncbi:9606">Human</span>
Dose-dependent induction of HLA-restricted T cell responses against autologous EBV-transformed B cells in infected hu-NSG mice. (A) Reconstituted NSG mice were infected with 105 or 106 RIU EBV. 6 wk after infection, human B cell-depleted splenocytes were incubated with autologous EBV-transformed B cells (LCLs) to measure EBV-specific IFN-gamma secretion using ELISPOT assays. IFN-gamma-specific spots per 105 cells are shown for a representative experiment with three mice in each group. One representative out of six experiments is shown. (B) Humanized NSG mice were infected with 106 RIU EBV. 6 wk after infection, splenocytes were harvested from control and infected animals, and T cell reactivity was evaluated by IFN-gamma ELISPOT assays under similar conditions as described in A. Staphylococcal enterotoxin B (SEB) superantigen and allogenic LCLs were used as positive and negative controls, respectively. Human HLA restriction was determined using inhibitory antibodies against HLA I and II as indicated. One representative out of two experiments is shown. Data represent means + SD. SFC, spot-forming cells.
###end p 18
###begin title 19
###xml 13 16 <span type="species:ncbi:10376">EBV</span>
Isolation of EBV-specific T cell clones
###end title 19
###begin p 20
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 376 384 376 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 437 440 437 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 645 646 641 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 830 838 826 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 877 884 873 880 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">167-176</sub>
###xml 894 902 890 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 931 932 927 928 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 963 964 959 960 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 978 980 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 1070 1078 1066 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 B</xref>
###xml 88 91 <span type="species:ncbi:10376">EBV</span>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 204 207 <span type="species:ncbi:10376">EBV</span>
###xml 362 365 <span type="species:ncbi:10376">EBV</span>
###xml 586 589 <span type="species:ncbi:10376">EBV</span>
###xml 944 947 <span type="species:ncbi:10376">EBV</span>
To analyze the peptide epitope specificity and effector functions of the in vivo-primed EBV-specific T cell responses, we isolated splenocytes from hu-NSG mice reconstituted with HLA-A2+ HPCs 10 wk after EBV infection. After labeling with CFSE, these splenocytes were stimulated with either autologous LCLs or a pool of 33 peptides derived from lytic and latent EBV antigens (Fig. 4 A). To enrich for LCL- or peptide-specific cells, CFSElow T cells were sorted after 6 d by flow cytometry, cloned by limiting dilution, and finally retested with either autologous LCLs or the pool of 33 EBV-derived peptides in IFN-gamma ELISPOT assays. Three CD8+ T cell clones recognized the library of 33 peptides, and subsequent testing against a matrix of smaller peptide libraries identified the individual peptides recognized by the clones (Fig. 4 A). All three clones recognized the LMP1167-176 peptide (Fig. 4 A), which is recognized by CD8+ T cells in EBV-infected HLA-A2+ individuals (10). Titration of the cognate peptide demonstrated high affinity recognition by the clones (Fig. 4 B).
###end p 20
###begin p 21
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Isolation of EBV-specific T cell clones from infected hu-NSG mice.</bold>
###xml 147 150 147 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 549 550 549 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 612 619 612 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">167-176</sub>
###xml 723 730 719 726 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">167-176</sub>
###xml 743 744 739 740 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 862 869 854 861 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">167-176</sub>
###xml 917 918 909 910 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 926 927 918 919 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 13 16 <span type="species:ncbi:10376">EBV</span>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 194 197 <span type="species:ncbi:10376">EBV</span>
###xml 255 258 <span type="species:ncbi:10376">EBV</span>
###xml 289 292 <span type="species:ncbi:10376">EBV</span>
###xml 329 332 <span type="species:ncbi:10376">EBV</span>
###xml 961 964 <span type="species:ncbi:10376">EBV</span>
Isolation of EBV-specific T cell clones from infected hu-NSG mice. (A) T cell clones were established by limiting dilution cloning from sorted CFSElow T cells of spleens from animals 6 wk after EBV infection. These T cells had proliferated in response to EBV-transformed B cells (LCLs) or EBV-derived peptides. The library of 33 EBV peptides that was used for the initial T cell proliferation was divided into the indicated matrix of peptide pools and used to assess the fine specificity of obtained T cell clones. Reactivity of one out of three CD8+ T cell clones specific for the HLA-A2-restricted peptide LMP1167-176 in IFN-gamma ELISPOT is shown. (B) Epitope affinity was determined by cognate peptide titration on LMP1167-176-specific CD8+ T cells in IFN-gamma ELISPOT assays. One representative out of two experiments is shown. (C) The cytotoxicity of LMP1167-176-specific (CD8-LMP1) and LCL-specific (#1-3) CD4+ and CD8+ T cell clones against autologous EBV-transformed B cells (LCLs) was assessed by flow cytometric TO-PRO-3-iodide exclusion assays at the indicated effector/target ratios (E/T). One representative out of three experiments is shown. (D) Degranulation and IFN-gamma production were evaluated after co-culture with autologous LCLs by flow cytometric surface staining for CD107a and intracellular IFN-gamma staining (percentages are shown). One representative out of three experiments is shown.
###end p 21
###begin p 22
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 31 32 31 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 232 233 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 317 318 313 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 354 355 350 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 395 396 391 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 467 475 463 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 C</xref>
###xml 555 563 547 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 D</xref>
###xml 617 620 <span type="species:ncbi:10376">EBV</span>
###xml 659 663 <span type="species:ncbi:10090">mice</span>
###xml 677 680 <span type="species:ncbi:10376">EBV</span>
We also identified CD4+ and CD8+ T cell clones that recognized the autologous LCLs in IFN-gamma ELISPOT assays. Subsequently, we compared the cytotoxicity of three of these LCL-specific clones (#1-3) and one of the LMP1-specific CD8+ T cell clones (CD8-LMP1) against autologous LCLs, and found that one of the two CD4+ T cell clones, the LCL-specific CD8+ T cell clone, and the LMP1-specific CD8+ T cell clone lysed autologous LCLs at similar effector/target ratios (Fig. 4 C). These T cells also degranulated and secreted IFN-gamma upon LCL recognition (Fig. 4 D). These data indicate that multifunctional cytotoxic EBV-specific T cells are primed in hu-NSG mice and can kill EBV-transformed B cells.
###end p 22
###begin title 23
###xml 31 34 <span type="species:ncbi:10376">EBV</span>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
Improved detection of dominant EBV peptide-specific CD8 T cell responses in HLA-A2 transgenic hu-NSG mice
###end title 23
###begin p 24
###xml 410 411 410 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 438 439 438 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 495 496 495 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 504 505 504 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1170 1178 1166 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 1284 1285 1280 1281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1440 1441 1432 1433 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1452 1453 1444 1445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1475 1476 1467 1468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1486 1487 1478 1479 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1693 1694 1685 1686 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1729 1730 1721 1722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1805 1808 1797 1800 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLY</sub>
###xml 1887 1890 1879 1882 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">YVL</sub>
###xml 1918 1921 1910 1913 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLG</sub>
###xml 1938 1946 1930 1938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 B</xref>
###xml 2151 2152 2143 2144 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2192 2195 2184 2187 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">YVL</sub>
###xml 2206 2214 2198 2206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 C</xref>
###xml 2301 2302 2293 2294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2308 2309 2300 2301 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2404 2407 2396 2399 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLG</sub>
###xml 33 36 <span type="species:ncbi:10376">EBV</span>
###xml 116 119 <span type="species:ncbi:10376">EBV</span>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 159 162 <span type="species:ncbi:10376">EBV</span>
###xml 225 228 <span type="species:ncbi:10376">EBV</span>
###xml 256 262 <span type="species:ncbi:9606">humans</span>
###xml 306 310 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 365 369 <span type="species:ncbi:10090">mice</span>
###xml 447 452 <span type="species:ncbi:9606">Human</span>
###xml 486 491 <span type="species:ncbi:9606">human</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
###xml 760 764 <span type="species:ncbi:10090">mice</span>
###xml 770 773 <span type="species:ncbi:10376">EBV</span>
###xml 837 841 <span type="species:ncbi:10090">mice</span>
###xml 860 863 <span type="species:ncbi:10376">EBV</span>
###xml 1067 1070 <span type="species:ncbi:10376">EBV</span>
###xml 1090 1094 <span type="species:ncbi:10090">mice</span>
###xml 1125 1129 <span type="species:ncbi:10090">mice</span>
###xml 1379 1383 <span type="species:ncbi:10090">mice</span>
###xml 1390 1393 <span type="species:ncbi:10376">EBV</span>
###xml 1410 1414 <span type="species:ncbi:10090">mice</span>
###xml 1611 1614 <span type="species:ncbi:10376">EBV</span>
###xml 1645 1649 <span type="species:ncbi:10090">mice</span>
###xml 1713 1716 <span type="species:ncbi:10376">EBV</span>
###xml 1798 1801 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1838 1841 <span type="species:ncbi:10376">EBV</span>
###xml 2036 2040 <span type="species:ncbi:10090">mice</span>
###xml 2055 2058 <span type="species:ncbi:10376">EBV</span>
###xml 2075 2079 <span type="species:ncbi:10090">mice</span>
###xml 2102 2105 <span type="species:ncbi:10376">EBV</span>
###xml 2125 2129 <span type="species:ncbi:10090">mice</span>
###xml 2344 2348 <span type="species:ncbi:10090">mice</span>
###xml 2517 2521 <span type="species:ncbi:10090">mice</span>
###xml 2569 2574 <span type="species:ncbi:9606">human</span>
###xml 2622 2625 <span type="species:ncbi:10376">EBV</span>
###xml 2676 2679 <span type="species:ncbi:10376">EBV</span>
###xml 2693 2699 <span type="species:ncbi:9606">humans</span>
Because we were able to identify EBV-derived peptide epitopes for our isolated T cell clones only occasionally from EBV-infected hu-NSG mice, we aimed to bias EBV-specific T cell recognition to peptide epitopes that dominate EBV-specific immune control in humans by introducing a HLA-A2 transgene into NSG mice. We reconstituted a group of regular NSG mice and NSG mice transgenic for HLA-A2 (NSG-A2) with CD34+ cells from the same HLA-A2+ donor. Human immune cells and, in particular, human CD4+ and CD8+ T cells developed in both groups of mice with similar frequencies and distributions (). Furthermore, transgenic expression of HLA-A2 did not influence homeostatic proliferation and survival of T cells (Fig. S2, B and C). We infected hu-NSG and hu-NSG-A2 mice with EBV, and 5 wk after infection we stimulated splenocytes from these mice with two pools of EBV-derived HLA-A2-restricted peptides, one containing 8 lytic epitopes and one containing 12 latent epitopes (). We detected IFN-gamma secretion by ELISPOT after stimulation with the lytic pool in all five EBV-infected hu-NSG-A2 mice, but only in four out of five mice after stimulation with the latent pool (Fig. 5 A). Notably, these latent responses were significantly lower than the lytic responses (11 vs. 70 SFU/2 x 105 cells; P = 0.04). Moreover, no IFN-gamma-secreting cells were detected in any of the control mice or in EBV-infected hu-NSG mice reconstituted with HLA-A2+ matching (n = 2) or nonmatching (n = 8) CD34+ cells against the used peptide pools ex vivo. Interestingly, after stimulation with autologous LCLs, splenocytes from both EBV-infected hu-NSG and hu-NSG-A2 mice responded similarly (107 vs. 124 SFU/2 x 105 cells). To detect EBV-specific CD8+ T cells directly, splenocytes were stained with control tetramers (HIV GAGSLY), and two well-characterized EBV tetramers derived from a lytic epitope (BRLF1YVL) and a latent epitope (LMP2CLG), respectively (Fig. 5 B). Although we did not detect any tetramer-positive cells in control hu-NSG and hu-NSG-A2 mice as well as in EBV-infected hu-NSG mice, in three out of five EBV-infected hu-NSG-A2 mice up to 2.7% of the CD8+ T cells stained positive with the BRLF1YVL tetramer (Fig. 5 C). These tetramer-positive cells had an activated phenotype that was exclusively CD45RO+HLA-DR+ (unpublished data). But, in these mice we also did not observe any cells positive for the LMP2CLG tetramer, possibly because their frequency was too low. These experiments suggest that HLA transgenic hu-NSG mice bias primary T cell responses of reconstituted human immune system components toward recognition of EBV-derived peptide epitopes that are dominant during EBV infection in humans.
###end p 24
###begin p 25
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 105 0 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Enhanced priming of CD8<sup>+</sup> T cell responses against dominant EBV peptides in HLA-A2 transgenic hu-NSG mice.</bold>
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 490 491 486 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 546 547 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 603 604 599 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 857 860 853 856 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SLY</sub>
###xml 888 891 884 887 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLG</sub>
###xml 924 927 920 923 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">YVL</sub>
###xml 59 62 <span type="species:ncbi:10376">EBV</span>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
###xml 230 233 <span type="species:ncbi:10376">EBV</span>
###xml 414 417 <span type="species:ncbi:10376">EBV</span>
###xml 458 461 <span type="species:ncbi:10376">EBV</span>
###xml 523 526 <span type="species:ncbi:10376">EBV</span>
###xml 624 629 <span type="species:ncbi:9606">human</span>
###xml 630 633 <span type="species:ncbi:10376">EBV</span>
###xml 751 754 <span type="species:ncbi:10376">EBV</span>
###xml 775 779 <span type="species:ncbi:10090">mice</span>
###xml 836 839 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 863 866 <span type="species:ncbi:10376">EBV</span>
###xml 897 900 <span type="species:ncbi:10376">EBV</span>
Enhanced priming of CD8+ T cell responses against dominant EBV peptides in HLA-A2 transgenic hu-NSG mice. (A) HLA-A2 transgenic and nontransgenic NSG mice were reconstituted with HLA-A2+ CD34+ HPCs from the same donor. 4 wk after EBV infection or mock treatment, splenocytes were restimulated for IFN-gamma ELISPOT assays with medium alone, staphylococcal enterotoxin B (SEB) as a positive control, the autologous EBV-transformed B cell line (LCLs), 8 lytic EBV antigen-derived dominant CD8+ T cell epitopes, and 12 latent EBV antigen-derived CD8+ T cell epitopes, which had been defined as dominant CD8+ T cell epitopes in human EBV carriers. The data summarize two independent experiments. (B and C) In parallel, tetramer staining on splenocytes of EBV-infected or control mice was performed ex vivo. Tetramers of HLA-A*0201 with the HIV gag aa 77-85 (GAGSLY), EBV LMP2 aa 426-434 (LMP2CLG), or EBV BRLF1 aa 109-117 (BRLF1YVL) peptides were used in costaining with anti-CD8 and analyzed by flow cytometry (percentages are shown). B shows a representative experiment and C shows the summary of two independent experiments. Horizontal bars represent means.
###end p 25
###begin title 26
###xml 13 16 <span type="species:ncbi:10376">EBV</span>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
Disseminated EBV-associated malignancies in T cell-depleted hu-NSG mice
###end title 26
###begin p 27
###xml 596 604 596 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 A</xref>
###xml 773 774 773 774 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 779 780 779 780 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 790 798 790 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 B</xref>
###xml 1386 1394 1386 1394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 B</xref>
###xml 1401 1402 1401 1402 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1867 1868 1867 1868 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1881 1882 1881 1882 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1889 1890 1889 1890 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1927 1928 1927 1928 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 1941 1942 1941 1942 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 2029 2044 2029 2044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, A and B</xref>
###xml 2183 2184 2183 2184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2192 2193 2192 2193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2302 2317 2302 2317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, C and D</xref>
###xml 2388 2389 2388 2389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2397 2398 2397 2398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2456 2457 2456 2457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 2477 2478 2473 2474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 2498 2499 2490 2491 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 2532 2533 2516 2517 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 2540 2541 2524 2525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 2583 2584 2567 2568 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 2604 2605 2584 2585 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 2625 2626 2601 2602 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 2659 2660 2627 2628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 2810 2811 2778 2779 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2819 2820 2787 2788 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 3282 3283 3250 3251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 3291 3292 3259 3260 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 42 45 <span type="species:ncbi:10376">EBV</span>
###xml 74 77 <span type="species:ncbi:10376">EBV</span>
###xml 92 95 <span type="species:ncbi:10376">EBV</span>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 163 166 <span type="species:ncbi:10376">EBV</span>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
###xml 306 309 <span type="species:ncbi:10376">EBV</span>
###xml 389 392 <span type="species:ncbi:10376">EBV</span>
###xml 516 519 <span type="species:ncbi:10376">EBV</span>
###xml 715 718 <span type="species:ncbi:10376">EBV</span>
###xml 728 732 <span type="species:ncbi:10090">mice</span>
###xml 1208 1211 <span type="species:ncbi:10376">EBV</span>
###xml 1369 1372 <span type="species:ncbi:10376">EBV</span>
###xml 1521 1524 <span type="species:ncbi:10376">EBV</span>
###xml 1592 1595 <span type="species:ncbi:10376">EBV</span>
###xml 1683 1686 <span type="species:ncbi:10376">EBV</span>
###xml 1747 1751 <span type="species:ncbi:10090">mice</span>
###xml 1763 1766 <span type="species:ncbi:10376">EBV</span>
###xml 1853 1857 <span type="species:ncbi:10090">mice</span>
###xml 1991 1994 <span type="species:ncbi:10376">EBV</span>
###xml 2105 2108 <span type="species:ncbi:10376">EBV</span>
###xml 2139 2143 <span type="species:ncbi:10090">mice</span>
###xml 2243 2246 <span type="species:ncbi:10376">EBV</span>
###xml 2421 2424 <span type="species:ncbi:10376">EBV</span>
###xml 2443 2446 <span type="species:ncbi:10376">EBV</span>
###xml 2570 2573 <span type="species:ncbi:10376">EBV</span>
###xml 3116 3120 <span type="species:ncbi:10090">mice</span>
###xml 3139 3144 <span type="species:ncbi:9606">human</span>
###xml 3145 3148 <span type="species:ncbi:10376">EBV</span>
###xml 3188 3192 <span type="species:ncbi:10090">mice</span>
###xml 3214 3217 <span type="species:ncbi:10376">EBV</span>
###xml 3232 3235 <span type="species:ncbi:10376">EBV</span>
###xml 3348 3351 <span type="species:ncbi:10376">EBV</span>
To study the role of these in vivo-primed EBV-specific T cells to control EBV infection and EBV-associated malignancies in hu-NSG mice, we depleted T cells before EBV infection using antibodies against CD4 and CD8 (). 4-5 wk after infection, mice were analyzed for the development of tumors as well as for EBV viral loads. Although we observed small splenic tumors in only 3 out of the 17 EBV-infected animals with or without isotype control antibody injection, all 11 T cell-depleted animals developed disseminated EBV-positive tumors in the spleen, mesenteric lymph node, kidney, and/or liver (Fig. 6 A). Histological analysis showed expansion of white pulp regions in the enlarged spleens of T cell-depleted and EBV-infected mice, which contained almost exclusively EBER+ CD20+ B cells (Fig. 6 B and not depicted). Morphologically these proliferations destroyed the underlying architecture of the tissue. They consisted of a polymorphous cell population composed of atypical large transformed cells (some of which resembled Reed-Sternberg variants), plasmacytoid cells, small lymphocytes, and histiocytes. Areas of coagulative necrosis were often also present. Overall, these proliferations resembled the EBV-associated polymorphic lesions seen in bone marrow and solid organ transplant recipients. The majority of these cells expressed EBNA2, once again indicating EBV latency III (Fig. 6 B). EBER+ cells located in the lymph node, liver, and kidney showed a similar phenotype ( and not depicted). In addition, lytic EBV replication, which was barely detectable during controlled primary EBV infection in vivo, as assessed by immunohistochemical staining for the immediate early EBV antigen BZLF1, was also increased in T cell-depleted hu-NSG mice 4 wk after EBV infection (). Furthermore, viral DNA loads increased significantly in T cell-depleted mice (3.2 x 106 vs. 1.9 x 105 per 106 splenocytes [P = 0.003] and 1.1 x 108 vs. 1.6 x 107 per spleen [P = 0.04]), indicating uncontrolled EBV infection after T cell depletion (Fig. 7, A and B). Notably, viral loads did not significantly differ between EBV-infected hu-NSG and hu-NSG-A2 mice (). To compare the contributions of CD4+ and CD8+ T cells to the T cell-mediated immune control of EBV infection, we then depleted T cell subsets separately (Fig. 7, C and D). Viral titers increased significantly both after the depletion of CD4+ and CD8+ T cells compared with EBV-infected animals (EBV, 6.4 x 105; alphaCD4, 1.9 x 106; alphaCD8, 3.2 x 106; and alphaCD4+alphaCD8, 1.3 x 107 per 106 splenocytes [P < 0.03]; and EBV, 1.5 x 107; alphaCD4, 7.2 x 107; alphaCD8, 1.2 x 108; and alphaCD4+alphaCD8, 8.6 x 108 per spleen [P < 0.03]). However, neither the separate depletion of CD4 or CD8 T cells increased the viral titers as much as the depletion of both CD4+ and CD8+ T cells in these experiments. Notably, we observed the occurrence of tumors in the spleens and mesenteric lymph nodes in all four pan-T cell-depleted and in three out of four CD8-depleted animals, but only in one out of four CD4-depleted animals. These results therefore demonstrate that hu-NSG mice are able to prime human EBV-specific T cell responses that protect mice against uncontrolled EBV infection and EBV-associated malignancies. Furthermore, both CD4+ and CD8+ T cells contribute to the successful immune control of EBV in this model.
###end p 27
###begin p 28
###xml 0 88 0 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Development of EBV-associated tumors in EBV-infected hu-NSG mice after T cell depletion.</bold>
###xml 421 422 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 479 480 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 563 564 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 608 609 600 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 15 18 <span type="species:ncbi:10376">EBV</span>
###xml 40 43 <span type="species:ncbi:10376">EBV</span>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 116 119 <span type="species:ncbi:10376">EBV</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 223 226 <span type="species:ncbi:10376">EBV</span>
###xml 268 271 <span type="species:ncbi:10376">EBV</span>
###xml 372 375 <span type="species:ncbi:10376">EBV</span>
###xml 392 396 <span type="species:ncbi:10090">mice</span>
###xml 398 401 <span type="species:ncbi:10376">EBV</span>
###xml 448 451 <span type="species:ncbi:10376">EBV</span>
###xml 468 472 <span type="species:ncbi:10090">mice</span>
###xml 474 477 <span type="species:ncbi:10376">EBV</span>
###xml 488 491 <span type="species:ncbi:10376">EBV</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
###xml 554 557 <span type="species:ncbi:10376">EBV</span>
###xml 593 597 <span type="species:ncbi:10090">mice</span>
###xml 793 796 <span type="species:ncbi:10376">EBV</span>
###xml 807 810 <span type="species:ncbi:10376">EBV</span>
###xml 859 863 <span type="species:ncbi:10090">mice</span>
###xml 939 942 <span type="species:ncbi:10376">EBV</span>
Development of EBV-associated tumors in EBV-infected hu-NSG mice after T cell depletion. (A) Disseminated tumors in EBV-infected animals after T cell depletion. T cell depletion in hu-NSG mice, which had been infected with EBV for 4-5 wk, resulted in splenomegaly and EBV-positive tumors either in the kidney, mesenteric lymph node, or liver (arrows). T cell-depleted and EBV-infected hu-NSG mice (EBV/alphaCD4+alphaCD8; n = 11) were compared with EBV-infected hu-NSG mice (EBV; n = 13), EBV-infected hu-NSG mice treated with isotype control antibodies (EBV/iso; n = 4), and uninfected hu-NSG mice (control; n = 11). Representative images are shown. Data summarize three independent experiments. (B) Immunohistological characterization of representative spleen sections of T cell-depleted and EBV-infected, EBV-infected and mock-treated, or uninfected hu-NSG mice. Splenic architecture was assessed by hematoxylin and eosin staining (HE), EBV-infected cells were identified by either EBER in situ hybridization (EBER) or staining with EBNA2-specific antibodies (EBNA2), and T and B cell content was characterized by CD3- and CD20-specific antibody staining, respectively. Bars: (HE) 500 microm; (CD3/EBER and CD20/EBNA2) 100 microm.
###end p 28
###begin p 29
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Elevated viral loads in T cell&#8211;depleted and EBV-infected hu-NSG mice.</bold>
###xml 434 435 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 833 834 833 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 875 876 875 876 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 942 943 942 943 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 962 963 958 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1161 1162 1145 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 1252 1253 1236 1237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1372 1373 1356 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 44 47 <span type="species:ncbi:10376">EBV</span>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 82 85 <span type="species:ncbi:10376">EBV</span>
###xml 149 152 <span type="species:ncbi:10376">EBV</span>
###xml 259 262 <span type="species:ncbi:10376">EBV</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 460 463 <span type="species:ncbi:10376">EBV</span>
###xml 630 634 <span type="species:ncbi:10090">mice</span>
###xml 641 644 <span type="species:ncbi:10376">EBV</span>
###xml 654 658 <span type="species:ncbi:10090">mice</span>
###xml 665 668 <span type="species:ncbi:10376">EBV</span>
###xml 715 719 <span type="species:ncbi:10090">mice</span>
###xml 751 754 <span type="species:ncbi:10376">EBV</span>
###xml 764 768 <span type="species:ncbi:10090">mice</span>
###xml 845 848 <span type="species:ncbi:10376">EBV</span>
###xml 908 911 <span type="species:ncbi:10376">EBV</span>
###xml 928 932 <span type="species:ncbi:10090">mice</span>
Elevated viral loads in T cell-depleted and EBV-infected hu-NSG mice. (A) Splenic EBV loads were determined by quantitative real-time PCR 4 wk after EBV infection. Viral titers were calculated from three independent experiments with a total of 39 animals. No EBV titers were detected in uninfected hu-NSG mice (control). Samples were analyzed at least in duplicates, and statistical significance was calculated using the Mann-Whitney U test. (B) Total splenic EBV loads were determined by multiplying splenic viral loads determined as in A with total splenocyte numbers determined by counting. Results are shown for seven control mice, nine EBV-infected mice, four EBV-infected and isotype control antibody-treated mice, and eight T cell-depleted and EBV-infected mice. Statistical significance was calculated using the Mann-Whitney U test. (C) EBV episome copy numbers in 106 splenocytes were determined in EBV-infected hu-NSG mice after CD4+ (alphaCD4) and CD8+ (alphaCD8) T cell single depletions, as well as double depletion (alphaCD4+alphaCD8). Composite data of two independent experiments are shown and were statistically analyzed using the Mann-Whitney U test. (D) Total viral loads per spleen were calculated from the viral copy numbers per 106 cells multiplied by the total counted splenocyte numbers. Statistical significance was assessed with the Mann-Whitney U test. Horizontal bars represent means.
###end p 29
###begin title 30
DISCUSSION
###end title 30
###begin p 31
###xml 282 286 282 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 292 293 288 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 293 296 289 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 118 121 <span type="species:ncbi:10376">EBV</span>
###xml 178 181 <span type="species:ncbi:10376">EBV</span>
###xml 233 236 <span type="species:ncbi:10376">EBV</span>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
###xml 321 326 <span type="species:ncbi:9606">human</span>
###xml 428 433 <span type="species:ncbi:9606">human</span>
###xml 535 538 <span type="species:ncbi:10376">EBV</span>
In this paper, we describe the first mouse model with protective immune control of the human persistent and oncogenic EBV. We demonstrate that primary T cell responses stabilize EBV load at high levels and prevent the development of EBV-associated malignancies. We propose that NOD-scid gammac-/- mice with reconstituted human immune system components provide a challenge model for testing the efficacy of vaccines against this human oncogenic virus, and for the characterization of innate and adaptive immune responses during primary EBV infection.
###end p 31
###begin p 32
###xml 80 99 76 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lymphocryptoviridae</italic>
###xml 162 164 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 310 312 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 314 316 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 339 341 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">22</xref>
###xml 441 443 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 445 447 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 515 516 511 512 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 519 520 515 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 580 582 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">22</xref>
###xml 816 818 808 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 820 822 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 972 974 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 1009 1012 997 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1018 1019 1002 1003 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 1019 1022 1003 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1127 1129 1111 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 1546 1547 1526 1527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 59 62 <span type="species:ncbi:10376">EBV</span>
###xml 198 203 <span type="species:ncbi:9606">human</span>
###xml 205 208 <span type="species:ncbi:10376">EBV</span>
###xml 293 308 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 329 337 <span type="species:ncbi:9491">tamarins</span>
###xml 397 402 <span type="species:ncbi:9606">human</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
###xml 460 468 <span type="species:ncbi:9491">tamarins</span>
###xml 555 558 <span type="species:ncbi:10376">EBV</span>
###xml 588 603 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 750 753 <span type="species:ncbi:10376">EBV</span>
###xml 832 836 <span type="species:ncbi:10090">mice</span>
###xml 838 841 <span type="species:ncbi:10376">EBV</span>
###xml 947 950 <span type="species:ncbi:10376">EBV</span>
###xml 1023 1027 <span type="species:ncbi:10090">mice</span>
###xml 1069 1072 <span type="species:ncbi:10376">EBV</span>
###xml 1112 1115 <span type="species:ncbi:10376">EBV</span>
###xml 1211 1214 <span type="species:ncbi:10376">EBV</span>
###xml 1295 1298 <span type="species:ncbi:10376">EBV</span>
###xml 1415 1418 <span type="species:ncbi:10376">EBV</span>
###xml 1439 1443 <span type="species:ncbi:10090">mice</span>
Although no similarly oncogenic gamma-herpesviruses of the EBV-containing genus Lymphocryptoviridae (lymphocryptoviruses) has been identified in rodents to date (19), priming of immune responses to human (EBV) or closely related monkey lymphocryptoviruses has been observed after infection in rhesus macaques (20, 21), cottontop tamarins (22), and in the two other novel models of immunocompetent human immune system reconstitution in mice (13, 17). Cottontop tamarins were able to prime MHC class II-restricted CD4+CD8+ T cells with cytotoxicity against EBV-transformed B cells (22). In rhesus macaques, strong cytotoxic and IFN-gamma-secreting T cell responses against the monkey virus homologues of the EBNA1 antigen and the immediate early lytic EBV antigen BZLF1 were consistently detected in infected animals (20, 21). In BLT mice, EBV infection elicited low levels of IFN-gamma-secreting, HLA-restricted T cell responses against autologous EBV-transformed B cells (17), and in reconstituted BALB/c Rag2-/- gammac-/- mice, T cell proliferation against autologous EBV-transformed B cells was detected after EBV infection (13). None of these animal models, however, has investigated the protective value of EBV-specific primary T cell responses in vivo, and the level of IFN-gamma-producing EBV-specific T cell responses was also about 5- to 10-fold lower than in the present study. In addition, we report that EBV infection in hu-NSG mice elicited cytotoxic- and epitope-specific primary T cell responses with protective effector functions (9).
###end p 32
###begin p 33
###xml 131 132 131 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 426 427 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 451 452 439 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 504 506 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 508 510 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 677 679 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 895 896 883 884 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 920 921 908 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1060 1062 1048 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">25</xref>
###xml 1064 1066 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 1417 1418 1405 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 1420 1422 1408 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 1819 1821 1807 1809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 39 42 <span type="species:ncbi:10376">EBV</span>
###xml 207 210 <span type="species:ncbi:10376">EBV</span>
###xml 320 324 <span type="species:ncbi:10090">mice</span>
###xml 494 502 <span type="species:ncbi:9606">patients</span>
###xml 559 562 <span type="species:ncbi:10376">EBV</span>
###xml 711 716 <span type="species:ncbi:9606">human</span>
###xml 741 745 <span type="species:ncbi:10090">mice</span>
###xml 773 776 <span type="species:ncbi:10376">EBV</span>
###xml 814 817 <span type="species:ncbi:10376">EBV</span>
###xml 1002 1005 <span type="species:ncbi:10376">EBV</span>
###xml 1006 1014 <span type="species:ncbi:9606">patients</span>
###xml 1101 1106 <span type="species:ncbi:9606">human</span>
###xml 1144 1148 <span type="species:ncbi:10090">mice</span>
###xml 1154 1157 <span type="species:ncbi:10376">EBV</span>
###xml 1212 1216 <span type="species:ncbi:10090">mice</span>
###xml 1258 1261 <span type="species:ncbi:10376">EBV</span>
###xml 1299 1302 <span type="species:ncbi:10376">EBV</span>
###xml 1348 1351 <span type="species:ncbi:10376">EBV</span>
###xml 1482 1486 <span type="species:ncbi:10090">mice</span>
###xml 1549 1552 <span type="species:ncbi:10376">EBV</span>
###xml 1637 1640 <span type="species:ncbi:10376">EBV</span>
###xml 1702 1710 <span type="species:ncbi:9606">patients</span>
###xml 1799 1806 <span type="species:ncbi:9606">patient</span>
###xml 1835 1838 <span type="species:ncbi:10376">EBV</span>
###xml 1855 1859 <span type="species:ncbi:10090">mice</span>
###xml 1868 1871 <span type="species:ncbi:10376">EBV</span>
###xml 1935 1938 <span type="species:ncbi:10376">EBV</span>
These primary immune responses control EBV infection at high levels of viral load, with massive expansion and activation of the CD8+ T cell compartment. These features are reminiscent of symptomatic primary EBV infection, called infectious mononucleosis (IM). Such a phenotype seems to be even more pronounced in hu-NSG mice, because they carry a 10-fold elevated viral load in their splenocytes, compared with approximately104 viral DNA copies per 106 peripheral blood mononuclear cells in IM patients (18, 23). Of course, this assumes that the frequency of EBV-infected cells is similar in peripheral blood and spleen during IM, as has been shown for healthy virus carriers (24). Therefore, the reconstituted human immune system in hu-NSG mice has difficulty controlling EBV infection, similar to chronic active EBV infection in bone marrow transplantation recipients. Indeed, approximately 105 viral DNA copies per 106 peripheral blood mononuclear cells have been observed in >50% of chronic active EBV patients, and these also occasionally develop tumors (25, 26). Nevertheless, the reconstituted human immune system protects most infected mice from EBV-associated malignancies. In contrast, T cell-depleted mice resemble, with their 10-fold increase in EBV viral loads and the dissemination of EBV-induced B cell lymphomas to various tissues, EBV-associated lymphoproliferative disease in transplant recipients (8, 27). In addition, in both immunocompetent and T cell-depleted mice, we primarily detect coexpression of EBER, EBNA2, and LMP1 in EBV-infected cells. This indicates latency III-type cells, which also form the basis of EBV-associated lymphoproliferative disease in immune-compromised patients. Furthermore, these lesions morphologically resemble those seen in the organ transplant patient population (28). Therefore, EBV-infected hu-NSG mice control EBV infection at high viral loads with hallmarks of IM and develop EBV-associated lymphoproliferative disease after T cell depletion.
###end p 33
###begin p 34
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 136 137 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 343 344 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 482 483 482 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 568 569 568 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 596 597 596 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 626 627 626 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 701 702 701 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 786 787 786 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 88 91 <span type="species:ncbi:10376">EBV</span>
###xml 388 391 <span type="species:ncbi:10376">EBV</span>
###xml 671 674 <span type="species:ncbi:10376">EBV</span>
###xml 722 725 <span type="species:ncbi:10376">EBV</span>
###xml 815 818 <span type="species:ncbi:10376">EBV</span>
###xml 967 972 <span type="species:ncbi:9606">human</span>
Both CD8+ and CD4+ T cells contribute to the control of viral infection. In the case of EBV, in vitro studies have demonstrated that CD8+ T cells mainly kill infected cells, whereas CD4+ T cells provide help for CD8+ T cells but can also directly target infected cells (9). Based on the results of our in vivo experiments, we conclude that CD4+ T cells contribute to the control of early EBV infection but are not able to restrict viral replication efficiently in the absence of CD8+ T cells. However, viral titers are further elevated upon additional depletion of CD8+ T cells in addition to CD4+ T cells, suggesting that CD4+ T cells can mediate some immune control of EBV (11). The inability of CD8+ T cells to control EBV infection on their own might reflect the requirement for CD4+ T cell help during primary EBV infection (12). This analysis demonstrates the usefulness of our in vivo model, which allows for the first time to dissect protective mechanisms of human lymphocyte compartments in vivo.
###end p 34
###begin p 35
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">29</xref>
###xml 928 932 928 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 938 939 934 935 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 939 942 935 938 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1006 1008 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 1251 1252 1247 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 1358 1360 1354 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 1600 1604 1596 1600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 1772 1774 1768 1770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">32</xref>
###xml 1933 1936 1929 1932 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1942 1943 1934 1935 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 1943 1946 1935 1938 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 2003 2005 1995 1997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 2324 2325 2316 2317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 2729 2731 2721 2723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 3557 3559 3549 3551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 68 71 <span type="species:ncbi:10376">EBV</span>
###xml 75 80 <span type="species:ncbi:9606">human</span>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 359 364 <span type="species:ncbi:9606">human</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
###xml 454 457 <span type="species:ncbi:10376">EBV</span>
###xml 524 527 <span type="species:ncbi:10376">EBV</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
###xml 644 647 <span type="species:ncbi:10376">EBV</span>
###xml 782 787 <span type="species:ncbi:10090">mouse</span>
###xml 840 843 <span type="species:ncbi:10376">EBV</span>
###xml 895 898 <span type="species:ncbi:10376">EBV</span>
###xml 943 947 <span type="species:ncbi:10090">mice</span>
###xml 979 984 <span type="species:ncbi:9606">human</span>
###xml 1011 1016 <span type="species:ncbi:9606">Human</span>
###xml 1090 1094 <span type="species:ncbi:10090">mice</span>
###xml 1156 1159 <span type="species:ncbi:10376">EBV</span>
###xml 1316 1319 <span type="species:ncbi:10376">EBV</span>
###xml 1376 1379 <span type="species:ncbi:10376">EBV</span>
###xml 1552 1555 <span type="species:ncbi:10376">EBV</span>
###xml 1569 1574 <span type="species:ncbi:9606">human</span>
###xml 1605 1609 <span type="species:ncbi:10090">mice</span>
###xml 1700 1704 <span type="species:ncbi:10090">mice</span>
###xml 1732 1737 <span type="species:ncbi:9606">human</span>
###xml 1909 1912 <span type="species:ncbi:10376">EBV</span>
###xml 1947 1951 <span type="species:ncbi:10090">mice</span>
###xml 1971 1976 <span type="species:ncbi:9606">human</span>
###xml 2036 2039 <span type="species:ncbi:10376">EBV</span>
###xml 2075 2078 <span type="species:ncbi:10376">EBV</span>
###xml 2132 2135 <span type="species:ncbi:10376">EBV</span>
###xml 2155 2159 <span type="species:ncbi:10090">mice</span>
###xml 2223 2226 <span type="species:ncbi:10376">EBV</span>
###xml 2262 2266 <span type="species:ncbi:10090">mice</span>
###xml 2294 2297 <span type="species:ncbi:10376">EBV</span>
###xml 2371 2377 <span type="species:ncbi:9606">humans</span>
###xml 2479 2484 <span type="species:ncbi:9606">human</span>
###xml 2511 2516 <span type="species:ncbi:10090">mouse</span>
###xml 2548 2553 <span type="species:ncbi:9606">human</span>
###xml 2623 2628 <span type="species:ncbi:9606">human</span>
###xml 2647 2650 <span type="species:ncbi:10376">EBV</span>
###xml 2674 2677 <span type="species:ncbi:10376">EBV</span>
###xml 2698 2702 <span type="species:ncbi:10090">mice</span>
###xml 2794 2799 <span type="species:ncbi:9606">human</span>
###xml 2832 2835 <span type="species:ncbi:10376">EBV</span>
###xml 2856 2861 <span type="species:ncbi:9606">human</span>
###xml 2911 2916 <span type="species:ncbi:10090">mouse</span>
###xml 3008 3014 <span type="species:ncbi:9606">humans</span>
###xml 3068 3071 <span type="species:ncbi:10376">EBV</span>
###xml 3116 3120 <span type="species:ncbi:10090">mice</span>
###xml 3206 3211 <span type="species:ncbi:10090">mouse</span>
###xml 3277 3280 <span type="species:ncbi:10376">EBV</span>
###xml 3354 3357 <span type="species:ncbi:10376">EBV</span>
###xml 3377 3381 <span type="species:ncbi:10090">mice</span>
###xml 3420 3425 <span type="species:ncbi:9606">human</span>
###xml 3426 3429 <span type="species:ncbi:10376">EBV</span>
###xml 3446 3449 <span type="species:ncbi:10376">EBV</span>
###xml 3530 3533 <span type="species:ncbi:10376">EBV</span>
###xml 3631 3636 <span type="species:ncbi:9606">human</span>
###xml 3664 3668 <span type="species:ncbi:10090">mice</span>
###xml 3725 3730 <span type="species:ncbi:9606">human</span>
###xml 3803 3806 <span type="species:ncbi:10376">EBV</span>
###xml 3847 3852 <span type="species:ncbi:9606">human</span>
Although we demonstrate protective primary immune responses against EBV in human immune system-reconstituted mice, there are several limitations to this model. The most striking is probably the lack of germinal center formation and difficulty in developing efficient as well as class-switched humoral immune responses. Although we found low concentrations of human IgG accumulating in the plasma of reconstituted mice over time, we were unable to detect EBV-specific IgG or IgM responses against the viral capsid antigen in EBV-infected mice (unpublished data). We nevertheless cannot exclude that humoral responses might develop against other EBV antigens and perhaps at later time points of infection, as we have observed for EBNA1 in an experimental vaccine study using the same mouse model (29). Indeed, IgM responses against the lytic EBV antigen BFRF3 were recently reported after 6 wk of EBV infection in a subset of NOD-scid gammac-/- mice with similar reconstitution of human immune compartments (30). Human B cell responses seem to be weak and slow in their development in hu-NSG mice. In addition, because more restricted expression patterns of EBV latent antigens have only been found in germinal center B cells of healthy virus carriers (6) and because latency I/II tumors are thought to originate from EBV-infected centrocytes or centroblasts (31), the study of EBV-associated Burkitt and Hodgkin lymphomas and T cell responses against these malignancies might be difficult in our model. Latency II tumors, however, have been observed in EBV-infected and human B cell-reconstituted NOD-scid mice, suggesting that these hosts allow signaling for germinal center formation. Because these mice are unable to reconstitute human T cells after HPC transfer alone (32), immunological studies are not possible in this model. Encouragingly, however, latency I/II patterns were recently also described in EBV-infected BALB/c Rag2-/- gammac-/- mice with reconstituted human immune system components (33), suggesting that the mode of EBV infection and/or of the developing EBV-specific immune control might allow different latent EBV infections even in mice with compromised germinal center development. Furthermore, the EBV-specific T cell response in hu-NSG mice seems to favor subdominant EBV-derived peptide epitopes (9), and we were unable to detect T cells of in humans dominant specificities ex vivo. A possible explanation for this might be the suboptimal selection of human T cells and their TCRs on mouse thymic epithelial cells and on human bone marrow-derived cells. Even so, others and we have reported that human T cells recognize EBV-infected B cells after EBV infection of hu-NSG mice (this study and reference 30), and this recognition can be blocked with antibodies against human MHC molecules, the selection of EBV-specific T cells on human bone marrow-derived cells and by H2 molecules on mouse stromal cells seems to favor different affinities and specificities than those observed in humans with matching MHC type. This shortcoming of dominant EBV epitope recognition during infection in NSG mice can be overcome by introducing HLA transgenes, such as HLA-A2 in our case, into this mouse background. Accordingly, we were able to detect latent and lytic EBV antigen-specific T cell responses against dominant peptide epitopes from EBV-infected hu-NSG-A2 mice ex vivo. Interestingly and similar to human EBV carriers, lytic EBV-specific T cells were detected with nearly 1 log higher frequencies than latent EBV antigen specificities (34). Therefore, HLA transgenes seem to overcome one of the limitations of human immune responses in hu-NSG mice, and allow this immunocompetent small animal model with human immune system components to develop protective T cell responses against EBV infection with similar specificities to human virus carriers.
###end p 35
###begin p 36
###xml 141 142 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 144 146 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 578 580 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">35</xref>
###xml 581 583 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">42</xref>
###xml 8 11 <span type="species:ncbi:10376">EBV</span>
###xml 372 375 <span type="species:ncbi:10376">EBV</span>
###xml 427 432 <span type="species:ncbi:9606">human</span>
###xml 470 473 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 522 526 <span type="species:ncbi:10090">mice</span>
###xml 546 551 <span type="species:ncbi:9606">human</span>
Because EBV-specific T cells are considered to be the cornerstone of immune control against this oncogenic and persistent gamma-herpesvirus (9, 10), we propose to further characterize the innate and adaptive immune responses that lead to this T cell-based immune control. We also plan to evaluate vaccine candidates for eliciting these protective T cell responses against EBV and other pathogens with exclusive tropism for the human hematopoietic lineage. This includes HIV, which has been shown to establish infection in mice with reconstituted human immune system components (35-42).
###end p 36
###begin title 37
MATERIALS AND METHODS
###end title 37
###begin title 38

###end title 38
###begin title 39
###xml 25 29 <span type="species:ncbi:10090">mice</span>
Preparation of humanized mice.
###end title 39
###begin p 40
###xml 23 27 19 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 9 27 9 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid IL2R&#947;<sup>null</sup></italic>
###xml 33 37 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 43 44 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 44 47 36 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 164 168 156 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</sup>
###xml 174 180 166 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tm1Wjl</sup>
###xml 261 265 253 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</sup>
###xml 375 379 367 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</sup>
###xml 385 391 377 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tm1Wjl</sup>
###xml 695 696 687 688 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 951 952 939 940 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 957 958 945 946 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1062 1063 1046 1047 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1137 1138 1121 1122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1279 1280 1263 1264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1285 1286 1269 1270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1437 1439 1421 1423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">15</xref>
###xml 1441 1443 1425 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 217 222 <span type="species:ncbi:10090">mouse</span>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
###xml 635 639 <span type="species:ncbi:10090">mice</span>
###xml 761 765 <span type="species:ncbi:10090">mice</span>
###xml 798 803 <span type="species:ncbi:9606">Human</span>
###xml 1064 1069 <span type="species:ncbi:9606">human</span>
###xml 1202 1206 <span type="species:ncbi:10090">mice</span>
###xml 1319 1323 <span type="species:ncbi:10090">mice</span>
###xml 1484 1489 <span type="species:ncbi:9606">human</span>
NOD/LtSz-scid IL2Rgammanull (NOD-scid gammac-/-) mice were obtained from the Jackson Laboratory and raised under specific pathogen-free conditions. The NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(HLA-A2.1)1Enge/Gck/Roly (NSG-A2) mouse was derived from crossing NOD.Cg-Prkdcscid Tg(HLA-A2.1) Enge/Dvs mice (a gift from D. Serreze, The Jackson Laboratory, Bar Harbor, ME) with NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice at Memorial Sloan-Kettering Cancer Center in the laboratory and with the generous support of R. O'Reilly (Memorial Sloan-Kettering Cancer Center, New York, NY). Brother and sister mating from the F2 offspring was performed with mice identified by PCR to be positive for both HLA-A*0201(A2+) and the IL-2Rgamma KO. Both heterozygous and homozygous NSG-A2 mice were used in these experiments. Human fetal liver was obtained from Advanced Bioscience Resources. The tissue was minced and treated with 2 mg/ml collagenase D (Roche) in HBSS with CaCl2/MgCl2 for 30 min at room temperature, followed by filtering through 70-microm nylon cell strainers (BD). CD34+ human hematopoietic stem cells (HSCs) were isolated using the Direct CD34+ Progenitor Cell Isolation Kit (Miltenyi Biotec). 2-5-d-old NSG mice were irradiated with 100 cGy and injected intrahepatically with 1-3 x 105 CD34+ HSCs 6 h after irradiation. The mice were bled 10-12 wk after engraftment, and peripheral lymphocytes were analyzed by FACS, as described previously (15, 16) to check for the reconstitution of the human immune system. Animal protocols were approved by the Institutional Animal Care and Use Committee of the Rockefeller University.
###end p 40
###begin title 41
###xml 0 3 <span type="species:ncbi:10376">EBV</span>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
EBV infection of mice and depletion of T cells.
###end title 41
###begin p 42
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 94 95 94 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 162 163 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 171 172 171 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 38 41 <span type="species:ncbi:10376">EBV</span>
###xml 153 158 <span type="species:ncbi:9606">human</span>
###xml 200 203 <span type="species:ncbi:10376">EBV</span>
Reconstituted mice were infected with EBV at different infectious doses ranging from 105 to 106 RIU by intraperitoneal injection. In select experiments, human CD4+ and CD8+ cells were depleted before EBV infection by intraperitoneal injection of 100 microg OKT-4 and 50 microg OKT-8 antibodies (BioLegend) on three consecutive days. To deplete T cells for the duration of the experiment, the same injection regimen was repeated 2 wk later.
###end p 42
###begin title 43
###xml 12 15 <span type="species:ncbi:10376">EBV</span>
Analysis of EBV-specific T cell responses.
###end title 43
###begin p 44
###xml 156 158 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib43">43</xref>
###xml 210 211 206 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 232 233 228 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 53 56 <span type="species:ncbi:10376">EBV</span>
###xml 200 205 <span type="species:ncbi:9606">human</span>
###xml 222 227 <span type="species:ncbi:10090">mouse</span>
4-10 weeks after infection, mice were sacrificed and EBV-specific T cell responses were analyzed using an IFN-gamma ELISPOT assay, as previously described (43). In brief, splenocytes were depleted of human CD19+ cells and mouse CD45+ using anti-CD19 and anti-CD45 microbeads (Miltenyi Biotec). The negative fraction after the depletion was stimulated with autologous LCLs at a ratio of 1:4 for 18 h. Spots were counted with an ELISPOT reader (Autoimmun Diagnostika GmbH). In blocking experiments, LCL recognition by T cells was blocked by preincubation of the target cells with 10 microg/ml anti-HLA-A/B/C (clone W6/32; eBioscience), anti-HLA-DR/DP/DQ (clone Tu39; BD), and a combination thereof.
###end p 44
###begin title 45
Cloning of peptide- and LCL-specific T cells.
###end title 45
###begin p 46
###xml 298 301 290 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 305 306 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 376 378 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib44">44</xref>
###xml 671 679 659 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 23 27 <span type="species:ncbi:10090">mice</span>
###xml 192 195 <span type="species:ncbi:10376">EBV</span>
###xml 509 512 <span type="species:ncbi:10376">EBV</span>
10 wk after infection, mice were sacrificed and splenocytes were isolated. Cells were then labeled with 0.5 microM CFSE (Invitrogen) and cultured in complete medium containing a library of 33 EBV peptides (1 microM each) or autologous irradiated LCLs at a ratio of 5:1, respectively. On day 6, CFSElow CD3+ cells were sorted by flow cytometry and cloned by limiting dilution (44). After initial expansion, individual clones were screened by IFN-gamma ELISPOT assays after restimulation with the library of 33 EBV peptides or autologous irradiated LCLs, respectively. Individual clones that recognized the library were further tested against a matrix of peptide subpools (Fig. 4 A) to identify the specific cognate peptides.
###end p 46
###begin title 47
Cytotoxicity assay.
###end title 47
###begin p 48
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib45">45</xref>
###xml 664 665 660 661 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 670 671 666 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 730 731 726 727 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 736 737 732 733 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 773 774 769 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 779 780 775 776 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 817 818 813 814 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 823 824 819 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
To evaluate the cytotoxic activity of T cell clones against the autologous LCLs, cytotoxicity assays were performed as previously described (45). In brief, target cells were labeled with PKH26 (Sigma-Aldrich) and incubated with T cell clones at the effector/target ratios. Cells were harvested after 4 h; TO-PRO-3-iodide (Invitrogen), a membrane-impermeable DNA stain, was added to each culture (0.5 microM final concentration); and cells analyzed by flow cytometry. Background and maximum TO-PRO-3-iodide stainings were obtained by incubation of target cells with medium and detergent, respectively. The percent specific lysis was calculated as (% TO-PRO-3-iodide+PKH26+ cells in effector/target cell co-culture - TO-PRO-3-iodide+PKH26+ cells in medium)/(% TO-PRO-3-iodide+PKH26+ cells in detergent - TO-PRO-3-iodide+PKH26+ cells in medium) x 100%.
###end p 48
###begin title 49
Degranulation assay.
###end title 49
###begin p 50
###xml 42 45 <span type="species:ncbi:10376">EBV</span>
To characterize the multifunctionality of EBV-specific T cell clones, we stimulated T cell clones at an effector/target ratio of 5:1 with autologous LCLs for 6 h in the presence of anti-CD107 antibody. To detect spontaneous degranulation and cytokine production, a control without LCL was included. After 1 h, 1 microg/ml monensin (Sigma-Aldrich) was added to all samples. At the end of the incubation, cells were fixed, permeabilized, stained with an anti-IFN-gamma antibody, and analyzed by flow cytometry.
###end p 50
###begin title 51
Analysis of homeostatic T cell proliferation and survival using 5-ethynyl-2'-deoxyuridine (EdU) and annexin-V.
###end title 51
###begin p 52
###xml 14 18 <span type="species:ncbi:10090">mice</span>
Reconstituted mice were injected once intraperitoneally with 100 microg EdU and sacrificed 24 h later. For EdU staining, cells were stained first for cell-surface antigens and then analyzed for EdU incorporation using the Click-iT EdU AF488 Cell Proliferation Assay Kit (Invitrogen) according to the manufacturer's instruction. For annexin-V staining, cells were stained first for cell-surface antigens and then stained with annexin-V and 7-AAD using the PE Annexin V Apoptosis Detection Kit (BD) according to the manufacturer's instructions.
###end p 52
###begin title 53
###xml 18 21 <span type="species:ncbi:10376">EBV</span>
Quantification of EBV viral loads by quantitative real-time PCR.
###end title 53
###begin p 54
###xml 521 526 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bcl-2</italic>
###xml 764 765 764 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 772 773 772 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">W</italic>
###xml 774 775 774 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 783 784 783 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 822 823 822 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">W</italic>
###xml 860 861 860 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 8 11 <span type="species:ncbi:10376">EBV</span>
###xml 342 345 <span type="species:ncbi:10376">EBV</span>
###xml 515 520 <span type="species:ncbi:9606">human</span>
###xml 689 692 <span type="species:ncbi:10376">EBV</span>
###xml 792 795 <span type="species:ncbi:10376">EBV</span>
###xml 831 834 <span type="species:ncbi:10376">EBV</span>
Splenic EBV viral DNA load was quantified by real-time PCR using a TaqMan PCR kit and a sequence detector (model 7900; Applied Biosystems). DNA was extracted using the Tissue and Blood DNA kit (QIAGEN) or the Wizard SV Genomic DNA purification system (Promega), according to the manufacturer's protocol. A region from the BamHI W fragment of EBV was amplified using primers 5'-GGACCACTGCCCCTGGTATAA-3' and 5'-TTTGTGTGGACTCCTGGGG-3', and detected with the fluorogenic probe FAM-TCCTGCAGCTATTTCTGGTCGCATCA-TAMRA. The human bcl-2 gene was amplified using primers 5'-CCTGCCCTCCTTCCGC-3' and 5'-TGCATTTCAGGAAGACCCTGA-3', and detected with the fluorogenic probe FAM-CTTTCTCATGGCTGTCC-TAMRA. The EBV BamHI W fragment copy number per cell was calculated using the formula N = 2 x W/B, where N is the EBV BamHI W copy number/cell, W is the EBV BamHI W copy number, and B is the bcl-2 copy number. All samples were tested in triplicates.
###end p 54
###begin title 55
Immunohistochemistry.
###end title 55
###begin p 56
###xml 443 446 <span type="species:ncbi:10376">EBV</span>
Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded tissue sections. The antibodies used in this study included CD20 (clone L26), CD8 (clone C8/144B), CD45 (clones 2B11 and PD7/26), CD68 (clone PGM1), EBNA2 (clone PE2), LMP1 (clone CS1-4; Dako), BZLF1 (clone BZ1; Santa Cruz Biotechnology, Inc.), CD3 (clone SP7; Thermo Fisher Scientific), CD21 (clone 2G9), and CD56 (ERIC-1; Novocastra). In situ hybridization for EBV was performed using an EBER probe (Vision Biosystems). Double immunohistochemical staining and dual in situ hybridization with immunohistochemical staining was performed using the Bond Max Autostainer (Leica). Formalin-fixed, paraffin-embedded tissue sections were deparaffinized, and endogenous peroxidase was inactivated. For the first antibody, antigen retrieval was performed using either the Bond Epitope Retrieval Solution 1 (ER1) or the Bond Epitope Retrieval Solution 2 (ER2) at 99-100degreesC for 20-30 min. After retrieval, the sections were incubated sequentially with the primary antibody for 25 min, the postprimary antibody for 15 min, and the polymer for 25 min (Bond Polymer Detection System; Vision Biosystems), followed by colorimetric development with diaminobenzidine (DAB; Vision Biosystems). For the subsequent staining with the second antibody, the sections were heated in either ER1 or ER2 at 99-100degreesC for 20-30 min, followed by blocking of endogenous alkaline phosphatase using Dual Endogenous Enzyme Block (Dako). The sections were then sequentially incubated with the second primary antibody, biotinylated link, and streptavidin-alkaline phosphatase (LSAB 2 System-AP; Dako) for 25, 15, and 30 min, respectively, followed by red chromagen development with permanent red (Dako). With respect to dual in situ hybridization-immunohistochemistry, in situ hybridization was performed first according to the manufacturer's instructions (Vision Biosystems) with colorimetric development using DAB, followed by immunostaining as described for the second antibody. Single immunohistochemical staining was performed as described for the first primary antibody.
###end p 56
###begin title 57
###xml 29 32 <span type="species:ncbi:10376">EBV</span>
Production of GFP-expressing EBV.
###end title 57
###begin p 58
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib46">46</xref>
###xml 294 295 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 15 18 <span type="species:ncbi:10376">EBV</span>
###xml 76 79 <span type="species:ncbi:10376">EBV</span>
###xml 107 110 <span type="species:ncbi:10376">EBV</span>
###xml 170 173 <span type="species:ncbi:10376">EBV</span>
GFP-expressing EBV was produced as previously described (46). In brief, the EBV lytic cycle was induced in EBV-positive AGS cells by addition of PMA and sodium butyrate. EBV was further purified by ultracentrifugation over a 25% sucrose step gradient and subsequently titered on Raji cells. GFP+ cells were counted 2 d later and titers were calculated in RIU.
###end p 58
###begin title 59
Tetramer staining.
###end title 59
###begin p 60
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">47</xref>
###xml 156 159 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 186 189 <span type="species:ncbi:10376">EBV</span>
###xml 223 226 <span type="species:ncbi:10376">EBV</span>
To stain CD8+ T cells, soluble tetrameric complexes of HLA-A*0201-peptide were produced using the methods of Busch et al. (47) with the following peptides: HIV gag aa 77-85 (SLYNTVATL), EBV LMP2 aa 426-434 (CLGGLLTMV), and EBV BRLF1 aa 109-117 (YVLDHLIVV). For staining with these reagents, hu-NSG splenocytes were incubated for 30 min at 37degreesC with 0.5 microg of HLA-A*0201-peptide tetramers (PE-conjugated) and washed. The cells were stained with anti-CD8 mAb conjugated with FITC (BD) for 30 min at 4degreesC and washed. The samples were analyzed in a flow cytometer.
###end p 60
###begin title 61
Statistical analysis.
###end title 61
###begin p 62
###xml 71 72 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 98 99 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
Statistical analyses were performed with the paired two-tailed Student t test or the Mann-Whitney U test, as indicated in the figures. The p-value of significant differences is reported. Plotted data represent means + SD unless otherwise stated.
###end p 62
###begin title 63
Online supplemental material.
###end title 63
###begin p 64
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</italic>
###xml 65 66 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 66 69 62 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 119 120 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 19 24 <span type="species:ncbi:9606">human</span>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 329 334 <span type="species:ncbi:9606">human</span>
###xml 353 357 <span type="species:ncbi:10090">mice</span>
###xml 392 395 <span type="species:ncbi:10376">EBV</span>
###xml 478 483 <span type="species:ncbi:9606">human</span>
###xml 495 498 <span type="species:ncbi:10376">EBV</span>
###xml 515 519 <span type="species:ncbi:10090">mice</span>
###xml 555 558 <span type="species:ncbi:10376">EBV</span>
###xml 580 585 <span type="species:ncbi:9606">human</span>
###xml 618 622 <span type="species:ncbi:10090">mice</span>
###xml 730 733 <span type="species:ncbi:10376">EBV</span>
###xml 757 761 <span type="species:ncbi:10090">mice</span>
###xml 782 785 <span type="species:ncbi:10376">EBV</span>
Fig. S1 shows that human immune cells reconstitute NOD-scid gammac-/- mice injected with human fetal liver-derived CD34+ HPCs. Fig. S2 demonstrates that transgenic expression of HLA-A2 does not affect overall reconstitution, homeostatic T cell proliferation, and T cell survival. Fig. S3 documents antibody-mediated depletion of human T cells in hu-NSG mice. Fig. S4 shows the development of EBV-associated tumors in nonlymphoid and secondary lymphoid organs after depletion of human T cells in EBV-infected hu-NSG mice. Fig. S5 demonstrates detection of EBV lytic replication in human B cells in the spleen of hu-NSG mice. Fig. S6 documents that transgenic expression of HLA-A2 does not significantly influence immune control of EBV infection in humanized mice. Table S1 lists the EBV-derived peptides used in this study. Online supplemental material is available at .
###end p 64
###begin title 65
Supplementary Material
###end title 65
###begin title 66
[Supplemental Material Index]
###end title 66
###begin p 67
###xml 135 139 135 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">scid</sup>
###xml 145 151 145 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tm1Wjl</sup>
###xml 179 184 <span type="species:ncbi:10090">mouse</span>
We thank Dr. R. Steinman for critically reading the manuscript, and Dr. R. O'Reilly for his generous support to derive the NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(HLA-A2.1)1Enge/Gck/Roly mouse strain by breeding.
###end p 67
###begin p 68
###xml 380 384 <span type="species:ncbi:4530">Rice</span>
###xml 622 626 <span type="species:ncbi:4530">Rice</span>
###xml 1061 1065 <span type="species:ncbi:4530">Rice</span>
C. Munz is supported by the Arnold and Mabel Beckman Foundation, the Alexandrine and Alexander Sinsheimer Foundation, the Burroughs Wellcome Fund, the Dana Foundation's Neuroimmunology program, the National Cancer Institute (grants R01CA108609 and R01CA101741), and the National Institute of Allergy and Infectious Diseases (grant RFP-NIH-NIAID-DAIDS-BAA-06-19). C. Munz and C.M. Rice received research funds from the Foundation for the National Institutes of Health (Grand Challenges in Global Health), and an Institutional Clinical and Translational Science Award (to the Rockefeller University Hospital). C. Munz, C.M. Rice, A. Chadburn, and J.W. Young are supported by the Starr Foundation. J.W. Young is supported by the National Cancer Institute (grants R01CA083070 and P01CA23766), by Mr. W.H. and Mrs. A. Goodwin of the Commonwealth Cancer Foundation for Research, and by the Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center. T. Strowig is a recipient of a predoctoral fellowship from the Boehringer Ingelheim Foundation. C.M. Rice and A. Ploss are also supported by the Greenberg Medical Research Institute, and A. Ploss is a recipient of a Kimberley Lawrence-Netter Cancer Research Discovery Fund award. J. Sashihara and J.I. Cohen are supported by the intramural research program of the National Institute of Allergy and Infectious Diseases, and J. Sashihara is also supported by the Japanese Herpesvirus Infection Forum.
###end p 68
###begin p 69
The authors have no conflicting financial interests.
###end p 69
###begin article-title 70
###xml 3 7 <span type="species:ncbi:10090">mice</span>
###xml 16 19 <span type="species:ncbi:9606">men</span>
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
Of mice and not men: differences between mouse and human immunology.
###end article-title 70
###begin article-title 71
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
Initial sequencing and comparative analysis of the mouse genome.
###end article-title 71
###begin article-title 72
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus: 40 years on.
###end article-title 72
###begin article-title 73
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus infection.
###end article-title 73
###begin article-title 74
###xml 26 44 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
###end article-title 74
###begin article-title 75
###xml 26 44 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell.
###end article-title 75
###begin article-title 76
###xml 40 58 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.
###end article-title 76
###begin article-title 77
Post-transplant lymphoproliferative disorders.
###end article-title 77
###begin article-title 78
###xml 41 47 <span type="species:ncbi:9606">humans</span>
###xml 62 80 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.
###end article-title 78
###begin article-title 79
###xml 35 53 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases.
###end article-title 79
###begin article-title 80
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Virus-specific CD4+ T cells: ready for direct attack.
###end article-title 80
###begin article-title 81
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Helping the CD8+ T-cell response.
###end article-title 81
###begin article-title 82
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Development of a human adaptive immune system in cord blood cell-transplanted mice.
###end article-title 82
###begin article-title 83
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 107 110 107 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 123 126 123 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 63 68 <span type="species:ncbi:9606">human</span>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
Monitoring the effect of gene silencing by RNA-interference in human CD34+ cells injected into newborn RAG2-/- gamma common-/- mice: functional inactivation of p53 in developing T cells.
###end article-title 83
###begin article-title 84
###xml 93 97 93 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 26 31 <span type="species:ncbi:9606">human</span>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chainnull mice.
###end article-title 84
###begin article-title 85
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 107 112 <span type="species:ncbi:9606">human</span>
Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.
###end article-title 85
###begin article-title 86
###xml 10 14 <span type="species:ncbi:10090">mice</span>
###xml 70 73 <span type="species:ncbi:10376">EBV</span>
Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1.
###end article-title 86
###begin article-title 87
Long-term shedding of infectious epstein-barr virus after infectious mononucleosis.
###end article-title 87
###begin article-title 88
Novel mammalian herpesviruses and lineages within the Gammaherpesvirinae: cospeciation and interspecies transfer.
###end article-title 88
###begin article-title 89
###xml 129 144 <span type="species:ncbi:9544">rhesus macaques</span>
The BZLF1 homolog of an Epstein-Barr-related gamma-herpesvirus is a frequent target of the CTL response in persistently infected rhesus macaques.
###end article-title 89
###begin article-title 90
###xml 7 8 7 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 31 49 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 85 100 <span type="species:ncbi:9544">rhesus macaques</span>
The CD8+ T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue.
###end article-title 90
###begin article-title 91
###xml 88 95 <span type="species:ncbi:9491">tamarin</span>
###xml 99 117 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 119 122 <span type="species:ncbi:10376">EBV</span>
Virus-specific cytotoxic T cell responses are associated with immunity of the cottontop tamarin to Epstein-Barr virus (EBV).
###end article-title 91
###begin article-title 92
###xml 21 39 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells.
###end article-title 92
###begin article-title 93
###xml 66 69 <span type="species:ncbi:10376">EBV</span>
The dispersal of mucosal memory B cells: evidence from persistent EBV infection.
###end article-title 93
###begin article-title 94
###xml 57 75 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Clinical and virologic characteristics of chronic active Epstein-Barr virus infection.
###end article-title 94
###begin article-title 95
###xml 28 46 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 66 69 <span type="species:ncbi:10376">EBV</span>
Two cases of chronic active Epstein-Barr virus infection in which EBV-specific cytotoxic T lymphocyte was induced after allogeneic bone marrow transplantation.
###end article-title 95
###begin article-title 96
###xml 12 30 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Spectrum of Epstein-Barr virus-associated diseases.
###end article-title 96
###begin article-title 97
Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders.
###end article-title 97
###begin article-title 98
###xml 61 66 <span type="species:ncbi:9606">human</span>
Targeting the nuclear antigen 1 of Epstein Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.
###end article-title 98
###begin article-title 99
###xml 16 21 <span type="species:ncbi:10090">mouse</span>
###xml 31 49 <span type="species:ncbi:10376">Epstein-Barr virus</span>
A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses.
###end article-title 99
###begin article-title 100
###xml 54 72 <span type="species:ncbi:10376">Epstein-Barr virus</span>
B cells under influence: transformation of B cells by Epstein-Barr virus.
###end article-title 100
###begin article-title 101
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 59 64 <span type="species:ncbi:9606">human</span>
###xml 82 100 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.
###end article-title 101
###begin article-title 102
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 39 42 39 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 50 53 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
###xml 74 92 <span type="species:ncbi:10376">Epstein-Barr virus</span>
CD34+ cord blood cell-transplanted Rag2-/- gamma c-/- mice as a model for Epstein-Barr virus infection.
###end article-title 102
###begin article-title 103
###xml 40 43 <span type="species:ncbi:10376">EBV</span>
Immune response and evasion in the host-EBV interaction. 
###end article-title 103
###begin article-title 104
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 54 59 <span type="species:ncbi:10090">mouse</span>
HIV-1 infection and pathogenesis in a novel humanized mouse model.
###end article-title 104
###begin article-title 105
###xml 94 97 94 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 103 106 103 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/-gammac-/- (RAG-hu) mice.
###end article-title 105
###begin article-title 106
###xml 28 32 28 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">null</sup>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 172 207 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Humanized NOD/SCID/IL2Rgammanull mice transplanted with hematopoietic stem cells under nonmyeloablative conditions show prolonged life spans and allow detailed analysis of human immunodeficiency virus type 1 pathogenesis.
###end article-title 106
###begin article-title 107
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 83 86 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 93 96 93 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 27 30 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice.
###end article-title 107
###begin article-title 108
###xml 24 29 <span type="species:ncbi:10090">mouse</span>
###xml 63 68 <span type="species:ncbi:9606">human</span>
###xml 92 127 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection.
###end article-title 108
###begin article-title 109
###xml 81 84 81 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 90 93 90 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice.
###end article-title 109
###begin article-title 110
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 104 109 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1.
###end article-title 110
###begin article-title 111
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of transcription peptide inhibitors on HIV-1 replication.
###end article-title 111
###begin article-title 112
###xml 43 61 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Dendritic cells initiate immune control of Epstein-Barr virus transformation of B lymphocytes in vitro.
###end article-title 112
###begin article-title 113
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 58 63 <span type="species:ncbi:9606">human</span>
Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells.
###end article-title 113
###begin article-title 114
###xml 25 30 <span type="species:ncbi:9606">human</span>
The abundant NK cells in human lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic.
###end article-title 114
###begin article-title 115
###xml 74 92 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus.
###end article-title 115
###begin article-title 116
Coordinate regulation of complex T cell populations responding to bacterial infection.
###end article-title 116
###begin p 117
###xml 26 29 <span type="species:ncbi:10376">EBV</span>
###xml 68 71 <span type="species:ncbi:10376">EBV</span>
Abbreviations used: EBER, EBV-encoded RNA; EBNA, nuclear antigen of EBV; HPC, hematopoietic progenitor cell; IM, infectious mononucleosis; LCL, lymphoblastoid cell line; LMP, latent membrane protein; RIU, Raji-infecting units.
###end p 117

